China’s biopharma ecosystem is reshaping how global pharmaceutical companies source innovation, build pipelines and structure deals. As Chinese-origin assets gain global validation and licensing values rise, China is becoming an increasingly strategic component of international growth strategies while regulatory and geopolitical complexity raises the stakes for companies deciding how deeply to engage, says GlobalData Healthcare, the pharmaceutical and life sciences intelligence arm of GlobalData, a leading intelligence and productivity platform.
GlobalData Healthcare has published a new Intelligence Briefing, “The Two-Way Street: From Stocking the Pipeline to Acquiring Development Platforms, The Next Frontier for China Biopharma,” following the second edition of Outsourcing in Clinical Trials & Clinical Trial Supply China (OCT & CTS China), held at the Renaissance Suzhou Hotel on 8 and 9 September 2026.
Why this matters for healthcare and life sciences leaders?
Sarah Nightingale, Asia-Pacific Principal Consultant at GlobalData Healthcare and co-author of the Intelligence Briefing, says: “China has solidified its position as the world’s second-largest drug developer of innovative drugs, with faster, cheaper trials. Big pharma is turning to China for the newest drug innovations, and the results are starting to speak for themselves, with massive waves of multi-billion-dollar licensing agreements from Western pharmaceutical giants.”
China’s out-licensing deals are also commanding a higher price point, with higher value and volume than ever before. In 2025, the value of China’s out-licensing deals reached $115 billion, with almost half of all US in-licensing now coming from China, according to GlobalData.
Deals such as Bristol Myers Squibb’s agreement with Jiangsu Hengrui Pharmaceuticals and AstraZeneca’s deal with CSPC, the largest deal of its kind in history at up to $18.5 billion in 2026, have moved from single-asset licensing to full development-platform acquisitions, while Akeso’s plenary-session lung cancer data at ASCO marked a first for a China-originating asset on that stage.
At the same time, the regulatory picture is tightening. The Biotech Investment National Security Act (BINSA) and heightened scrutiny of China-developed drugs intended for US commercialization is adding a further layer of complexity for deal teams, wherever they sit.
Peter Barschdorff, Vice President at GlobalData Consulting and co-author of the Intelligence Briefing, says: “China is not a side conversation in global biopharma strategy anymore. The organizations getting this right are the ones which have honestly assessed where they stand today and built a deliberate path from there. That is precisely the gap this Briefing, and the Maturity Model at its center, is designed to close.”
A four-stage lens on China readiness
At the heart of the Intelligence Briefing is GlobalData’s China Biopharma Maturity Model, a four-stage framework helping healthcare organizations benchmark their China footprint, from limited presence to deeply integrated operations.
The model enables executives to assess their position and identify practical next steps, from licensing and acquisitions to closer monitoring of China’s rapidly evolving market.
Nightingale concludes: “Every client conversation about China ends up asking the same underlying question. It is not just about ‘what is happening,’ it is ‘where do we stand, and what should we practically do next?’ That is exactly what the Maturity Model gives leadership teams: an objective, honest reference point for a market that is of strategic interest for all.”
From Suzhou to the US
Nightingale represented GlobalData Healthcare at the OCT & CTS China, delivering the opening keynote on China’s biopharma opportunity to 300 senior clinical operations, supply chain and business development leaders from across the region’s biopharma and CRO community. Barschdorff will bring these insights to the US and global audience at Arena International’s OCT New England conference in October 2026.
